Solvay and Watson fight US FTC and claim Androgel settlements are legal
This article was originally published in Scrip
Solvay Pharmaceuticals and Watson Pharmaceuticals have jointly filed a motion seeking dismissal of the US Federal Trade Commission's January 29th lawsuit alleging that patent settlements over the testosterone supplement Androgel restrained competition. The companies argue that the settlements are legal under an appeals court's precedent. The motion was filed in late July in the US District Court for the Northern District of Georgia.